[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"feasibility\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:feasibility":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,94,118],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100607926","hiv-self-testing-for-partners-of-hiv-uninfected-postpartum-women-100607926",false,"NCT07194902","HIV Self-testing for Partners of HIV-uninfected Postpartum Women","HIV Self-testing for Partners of HIV-uninfected Postpartum Women to Facilitate PrEP and Antiretroviral Therapy Uptake to Promote HIV Treatment and Prevention","Female Inclusion Criteria:\n\n* woman\n* Age ≥18\n* ≥30 weeks pregnant per medical record due date\n* non-reactive third trimester HIV test (verified from their antenatal care chart)\n* reporting at least one unknown-serostatus partner\n* fluent in English or isiZulu\n* willing to give researchers permission to contact them for repeated assessments\n* able to provide informed consent\n\nMale Inclusion Criteria: partners meeting the inclusion criteria as described above, and who complete verification questions to confirm their identity and status as the partners of the enrolled female participants. Additional inclusion criteria for men include:\n\n* man\n* Age ≥18\n* partner of enrolled women, confirmed via couples verification tool\n* fluent in English or isiZulu\n* willing to give researchers permission to contact them\n* able to provide informed consent.\n\nExclusion Criteria: Individuals with significant psychiatric illness that could interfere with participation or the ability to provide informed consent will be excluded at the discretion of the study team.",true,"ALL","18 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study is to test the feasibility and acceptability of a combination intervention to promote HIV self-testing (HIVST) for Partners and PrEP uptake for HIV-uninfected Postpartum Women (\"H4P\"). H4P includes evidence-based cognitive behavioral therapy (CBT) strategies, such as communication skills training, motivational interviewing, and problem-solving. The investigators will conduct a randomized pilot trial of the H4P intervention to evaluate the feasibility, acceptability, and preliminary effectiveness of a multi-step PrEP uptake and HIV self-test kit intervention for postpartum HIV-uninfected women (N = 60 and their male partners) who report a partner of unknown serostatus, and their partners, in the province of KwaZulu-Natal, South Africa.",[27,28,29,30,31,32],"HIV Self-testing","Male Partners of HIV-negative Postpartum Women","PrEP Uptake","Feasibility","Acceptability","HIV Prevention",[32,34,35],"PrEP","HIV Self-Testing","RECRUITING","2026-03-19",{"date":39,"type":40},"2026-03-23","ACTUAL",{"date":37,"type":40},{"date":43,"type":21},"2026-08-28",{"name":45,"class":46},"Massachusetts General Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":16,"sex":56,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":47},"100582120","feasibility-of-remote-ectg-monitoring-homehospital-in-complicated-pregnancies-100582120","NCT06859177","Feasibility of Remote eCTG Monitoring Home@Hospital in Complicated Pregnancies","Remote Electrophysiological Cardiotocography (eCTG), Evaluation of Feasibility in (a Selected Group of) Complicated Pregnancies From 32 Until 37 Weeks Gestational Age in a Home@Hospital Setting: a Prospective Cohort Study","HASTA","Inclusion Criteria:\n\nIn order to be eligible to participate in this study, a subject must meet all of the following criteria:\n\n* Minimum age of 18 years old\n* Pregnant patients with a gestational age between 32+0 and 36+6 weeks and days\n* Singleton pregnancy\n* Any indication for fetal monitoring at least twice per week (e.g.):\n\n  * Pre-eclampsia (PE)\n  * Fetal growth restriction (FGR)\n  * Preterm pre-labor rupture of membranes (PPROM)\n* Absence of exclusion criteria \\> 24 hours after admission.\n* Oral and written informed consent is obtained.\n\nExclusion Criteria:\n\nA potential subject who meets any of the following criteria will be excluded from participation in this study:\n\n* An indication for intravenous medication\n* Blood pressure \\>160\u002F110 A millimeter of mercury (mmHg)\n* Absent-\u002For reversed flow umbilical artery Doppler\n* Hemolysis Elevated Liver enzymes and Low Platelets (HELLP) (Table 1)\n* Obstetric intervention expected \\\u003C48 hours, e.g. due to:\n\n  * Non reassuring cardiotocography (CTG)\n  * Active vaginal blood loss\n  * Signs of abruption placentae\n  * Meconium stained amniotic fluid\n  * Signs of chorioamnionitis\n* Patients admitted with a clinical diagnosis of sepsis with hypotension (i.e. septic shock).\n* Insufficient knowledge of Dutch or English language\n* Insufficient comprehension of instruction Nemo Remote® or patient information\n* Fetal and\u002For maternal cardiac arrhythmias\n* Contraindications to abdominal patch placement (dermatologic diseases of the abdomen precluding preparation of the abdomen with abrasive paper)\n* Patients connected to an external or implanted electrical stimulator, such as Transcutaneous Electro Neuro Stimulation (TENS) and pacemaker (because of disturbance of the electrophysiological signal).","FEMALE",{"count":58,"type":21},60,[24],"The objective of this single center, interventional cohort study is to evaluate the feasibility of remote electrophysiological cardiotocography (eCTG) monitoring in complicated pregnancies in a home@hospital setting.\n\nThe primary objective is to assess:\n\n• The success rate of the self-administered eCTG measurement\n\nThe secondary objective is to asses:\n\n* Maternal and perinatal outcomes\n* Patients wellbeing and satisfaction.\n* Healthcare professionals' (HCPs') satisfaction\n* Analysis of antenatal costs\n\nParticipants will:\n\n* Self-administer remote eCTG monitoring once daily during admission (or at least twice weekly at the outpatient clinic)\n* Self-measure their blood pressure, heartrate and temperature\n* Enter the measurements, symptoms and worries into an application on their telephone.\n* Answer questionnaires at 3 moments during the study, assessing their wellbeing and satisfaction of the received care and self-administered remote monitoring device.",[62,63,30],"Pregnancy Related","Remote Monitoring",[65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84],"feasibility","remote","complicated pregnancies","antenatal","Non invasive fetal electrocardiography (NI-fECG)","electrophysiological cardiotocography (eCTG)","high-risk pregnancies","pregnancy","maternal and fetal monitoring","monitoring","electrophysiological","non invasive","preterm pre-labor rupture of membranes (PPROM)","pre-eclampsia (PE)","fetal growth restriction (FGR)","home monitoring","remote monitoring","second trimester","self-administered","satisfaction","2025-09-23",{"date":87,"type":40},"2025-09-26",{"date":89,"type":40},"2025-03-25",{"date":91,"type":21},"2026-12",{"name":93,"class":46},"Maxima Medical Center",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":47},"100580801","feasibility-trial-of-darwin-oncotreat-and-oncotarget-precision-medicine-testing-100580801","NCT06842030","Feasibility Trial of Darwin OncoTreat and OncoTarget Precision Medicine Testing","Feasibility Trial of Darwin OncoTreat and OncoTarget Precision Medicine Testing to Improve Outcomes for Patients With Limited Metastatic Disease That Failed First-Line Systemic Therapy","Inclusion Criteria:\n\n* Patients age ≥18 years with metastatic solid tumor who are candidates for comprehensive involved site radiotherapy to all areas of disease seen on whole body imaging.\n* Patients with brain metastases are eligible provided they qualify as oligometastases (up to 10 lesions based on the SABR-COMET-10 trial) and are treatable with radiotherapy to all areas of visible disease.\n* Patients with adequate bone marrow (absolute neutrophil ≥1000, hemoglobin ≥ 9 g\u002Fdl, platelets ≥100,000), kidney (creatinine ≤1.5 times upper limit of normal) and liver (bilirubin ≤1.5 times upper limit of normal).\n* Patients being treated by radiation oncology at Good Samaritan University Hospital.\n\nExclusion Criteria:\n\n* Patients with an estimated median survival of less than 6 months using the published and validated NEAT methodology.\n* Patients who are pregnant and\u002For breast feeding or those with severe uncontrolled cardiac, pulmonary, infectious or organic brain disease.",{"count":102,"type":21},20,[24],"This is a feasibility trial to assess use of OncoTarget and OncoTreat testing in a basket design of patients with oligmetastasis across various solid tumor histology. Eligible oligometastatic patients that are receiving radiation therapy (n=20) will undergo mandatory tumor biopsy prior to precision medicine testing. Formalin fixed paraffin embedded tissue with \\>50% tumor will be sent to the Laboratory of Personalized Genomic Medicine at Columbia University Medical Center for Darwin OncoTarget and OncoTreat testing. This will be supplementing routine clinical care with the goal of improving outcomes. The treating oncologist will decide to administer standard of care systemic therapy or proceed with treatment recommended by precision medicine testing. Feasibility outcomes include the ability to have the OncoTarget and OncoTreat test performed based on tumor type and pathology, ability to procure agents, change in medication use, and identification of unknown barriers. This study is assessing the use of precision medicine in a population has documented poor outcomes with implications aimed at improving these outcomes.",[106,107,30],"Personalized Medicine","Oligometastatic Disease","NOT_YET_RECRUITING","2025-02-18",{"date":111,"type":40},"2025-02-24",{"date":113,"type":21},"2025-03-10",{"date":115,"type":21},"2027-04-10",{"name":117,"class":46},"Good Samaritan Hospital Medical Center, New York",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":16,"sex":17,"minAge":124,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":128,"phases":4,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":4},"100550543","a-pilot-study-of-deep-cervical-lymphatic-venous-anastomosis-in-the-treatment-of-alzheimers-disease-100550543","NCT06448442","A Pilot Study of Deep Cervical Lymphatic-venous Anastomosis in the Treatment of Alzheimer's Disease","Inclusion Criteria:\n\n* a. aged 50-90 years (\\> or equal to 50 years old, \\\u003C or equal to 90 years old) were evaluated as Alzheimer's disease group according to the 2018 NIA-AA diagnostic criteria; B. signed by the patient or family informed consent; c. Patients with mild or moderate disease, 11≤MMSE≤26; d. Subjects with primary school education or above can complete the prescribed scale evaluation; The diagnosis of AD was confirmed by e.PET or cerebrospinal fluid examination\n\nExclusion Criteria:\n\n* a. any other disease that can cause cognitive impairment (e.g., dementia with Lewy bodies, frontotemporal dementia, Parkinson's disease dementia, etc.), intracranial mass impairing cognition, history of traumatic brain injury, normal pressure hydrocephalus, history of clinically significant cerebrovascular disease; b. Excluding other diseases affecting the nervous system, including nervous system infection, epilepsy, and systemic diseases affecting the function of the nervous system; c. Inability to cooperate with cognitive testing; d. Presence of contraindications to MRI examination (e.g., pacemakers, stents, claustrophobia, severe psychiatric symptoms, etc.).","50 Years","90 Years",{"count":127,"type":21},8,"OBSERVATIONAL","Alzheimer's disease (AD) is the most prevalent form of dementia, affecting 3-4% of the population over a lifetime. It's characterized by abnormal Amyloid-beta (Aβ) and tau protein expression and accumulation in the central nervous system, leading to amyloid plaques and neurofibrillary tangles. While current treatments can slow cognitive decline, there's no cure.\n\nThe discovery of the \"glymphatic-meningeal lymphatic\" system has shed new light on cerebrospinal fluid circulation, showing it has a similar interstitial fluid system to peripheral lymphatic circulation. This system helps clear waste and transport nutrients in the brain, known as the glymphatic phenomenon. The deep cervical lymph nodes, part of this system, are crucial for cerebrospinal fluid drainage and are linked to the clearance of AD-related proteins.\n\nAging and inflammation can impair deep cervical lymph node function, increasing cerebrospinal fluid drainage pressure and potentially contributing to AD progression. Lymphatic anastomosis, a surgical technique used for lymphedema and other conditions, is being explored as a potential treatment to alleviate neurodegenerative disease by reducing cerebrospinal fluid pressure and clearing metabolic waste.",[131,30,132],"Safety Issues","Therapeutic Value","2024-06-03",{"date":135,"type":40},"2024-06-07",{"date":137,"type":21},"2024-08-01",{"date":139,"type":21},"2028-08-01",{"name":141,"class":46},"Second Affiliated Hospital, School of Medicine, Zhejiang University"]